journal article·2024-04

Radiotherapy Resistance of 3D Bioprinted Glioma via ITGA2/p‐AKT Signaling Pathway

Dongdong Liu, Haotian Tian, Huaixu Li, Jianyu Nie, Zhenyu Han, Guozhang Tang, Peng Gao, Hongwei Cheng, Xingliang Dai

Advanced Healthcare Materials· Volume 13· Issue 9
Publisher page

Abstract

Abstract Due to the inherent radiation tolerance, patients who suffered from glioma frequently encounter tumor recurrence and malignant progression within the radiation target area, ultimately succumbing to treatment ineffectiveness. The precise mechanism underlying radiation tolerance remains elusive due to the dearth of in vitro models and the limitations associated with animal models. Therefore, a bioprinted glioma model is engineered, characterized the phenotypic traits in vitro, and the radiation tolerance compared to 2D ones when subjected to X‐ray radiation is assessed. By comparing the differential gene expression profiles between the 2D and 3D glioma model, identify functional genes, and analyze distinctions in gene expression patterns. Results showed that 3D glioma models exhibited substantial alterations in the expression of genes associated with the stromal microenvironment, notably a significant increase in the radiation tolerance gene ITGA2 (integrin subunit A2). In 3D glioma models, the knockdown of ITGA2 via shRNA resulted in reduced radiation tolerance in glioma cells and concomitant inhibition of the p‐AKT pathway. Overall, 3D bioprinted glioma model faithfully recapitulates the in vivo tumor microenvironment (TME) and exhibits enhanced resistance to radiation, mediated through the ITGA2/p‐AKT pathway. This model represents a superior in vitro platform for investigating glioma radiotherapy tolerance.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: 3D Printing in Biomedical Research · Cancer Cells and Metastasis · Glioma Diagnosis and Treatment

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Neurosurgery the First Affiliated Hospital of Anhui Medical University Hefei Anhui 230001 China

Department of Medical Imaging Technology the First Clinical College of Anhui Medical University Hefei Anhui 230032 China

Department of Clinical Medicine the Second Clinical College of Anhui Medical University Hefei Anhui 230032 China

Department of Research & Development East China Institute of Digital Medical Engineering Shangrao Jiangxi 334000 China

Funding

Natural Science Foundation of Anhui Province

References (43)

Show source-provided references
1. 10.1093/neuonc/noab20010.1093/neuonc/noab200 ↗
2. 10.1016/j.biomaterials.2022.12191710.1016/j.biomaterials.2022.121917 ↗
3. 10.1093/neuonc/nov14510.1093/neuonc/nov145 ↗
4. 10.1038/ncpneuro028910.1038/ncpneuro0289 ↗
5. 10.2147/DDDT.S4958410.2147/DDDT.S49584 ↗
6. 10.1021/acsami.2c0665810.1021/acsami.2c06658 ↗
7. 10.1016/j.cell.2022.04.03810.1016/j.cell.2022.04.038 ↗
8. 10.3389/fonc.2022.102271610.3389/fonc.2022.1022716 ↗
9. Filipiak‐Duliban A. · Int. J. Mol. Sci. · 2022 · 23
10. 10.1038/nrm387310.1038/nrm3873 ↗
11. 10.1016/j.biomaterials.2015.10.07610.1016/j.biomaterials.2015.10.076 ↗
12. Radajewska A. · Am. J. Cancer Res. · 2021 · 11 · 4931
13. 10.1016/j.actbio.2016.04.03210.1016/j.actbio.2016.04.032 ↗
14. 10.3389/ftox.2021.65625410.3389/ftox.2021.656254 ↗
15. Ho T. · Cells · 2021 · 10
16. 10.1021/acsbiomaterials.2c0099810.1021/acsbiomaterials.2c00998 ↗
17. 10.1039/D2BM02060B10.1039/D2BM02060B ↗
18. 10.1016/j.radonc.2009.07.00410.1016/j.radonc.2009.07.004 ↗
19. 10.1158/0008-5472.CAN-12-353710.1158/0008-5472.CAN-12-3537 ↗
20. 10.1002/adhm.20230298810.1002/adhm.202302988 ↗
21. 10.1021/acsami.2c0370610.1021/acsami.2c03706 ↗
22. Antonelli F. · Int. J. Mol. Sci. · 2023 · 24
23. Strand Z. · Cancers · 2023 · 15
24. 10.1038/nbt.295810.1038/nbt.2958 ↗
25. Kim J. · Micromachines · 2021 · 12
26. 10.1021/acsabm.0c0079110.1021/acsabm.0c00791 ↗
27. 10.1038/s41422-020-0338-110.1038/s41422-020-0338-1 ↗
28. 10.1002/cpmc.12910.1002/cpmc.129 ↗
29. 10.1016/j.ccell.2017.02.01310.1016/j.ccell.2017.02.013 ↗
30. 10.1088/1758-5090/8/4/04500510.1088/1758-5090/8/4/045005 ↗
31. Besselaar A. M. H. P. · Clin. Chem. Lab. Med. · 2017 · 55
32. 10.1039/D0SM01455A10.1039/D0SM01455A ↗
33. 10.1039/C9RA08162C10.1039/C9RA08162C ↗
34. Zhou C. · Cancer Lett. · 2022 · 547
35. 10.1186/s13046-019-1419-110.1186/s13046-019-1419-1 ↗
36. 10.1016/j.bioorg.2022.10631710.1016/j.bioorg.2022.106317 ↗
37. 10.7150/ijbs.6993410.7150/ijbs.69934 ↗
38. 10.1186/s13578-022-00887-310.1186/s13578-022-00887-3 ↗
39. 10.1002/bit.2745910.1002/bit.27459 ↗
40. 10.1002/jcp.2544110.1002/jcp.25441 ↗
41. 10.3181/0904-MR-13810.3181/0904-MR-138 ↗
42. 10.1016/j.cell.2017.04.00110.1016/j.cell.2017.04.001 ↗
43. 10.1074/jbc.M70304220010.1074/jbc.M703042200 ↗